Page Title
Drug Development Pipeline
BX004-A
Status
DiscontinuedTherapeutic Approach
Anti-Infective
This program studied BX004-A, a type of phage therapy intended to treat Pseudomonas aeruginosa infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. They are found in the environment and are the predators of bacteria in nature. “Phage therapy” refers to the use of these bacteriophages to treat an infection in a person.
In lab studies, BX004-A was shown to be active against antibiotic-resistant strains of P. aeruginosa and demonstrated the ability to penetrate biofilm, a naturally forming structure that makes bacteria more resistant to antibiotics.
Status
A Phase 2 study of BX004-A in adults with CF who have chronic Pseudomonas aeruginosa infections was conducted. During the study, participants experienced adverse events more frequently than expected. An independent data monitoring committee performed a safety review, after which the sponsor decided not to continue this study. No further development in CF is planned at this time.
Sponsor
This program was sponsored by BiomX and partially funded by the Cystic Fibrosis Foundation. Clinical trials were conducted through the Therapeutics Development Network.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More